Published: 2025/11/25 18:46:58
Abbott to Acquire Exact Sciences for $18.8 Billion
Table of Contents
abbott Laboratories announced on November 25, 2025, that it will acquire Exact Sciences Corporation for $18.8 billion in cash and stock. The deal aims to strengthen Abbott’s diagnostic portfolio,notably in the area of cancer screening and diagnostics,and is expected to close in the second quarter of 2026.
transaction details
Under the terms of the agreement, Exact Sciences shareholders will receive $77.50 in cash plus 0.15 shares of Abbott stock for each share of Exact Sciences they own. The transaction values Exact Sciences at approximately $18.8 billion, including the assumption of Exact Sciences’ estimated net debt of $1.8 billion. The acquisition has been unanimously approved by the boards of directors of both companies and is subject to shareholder approval from Exact Sciences, and also customary closing conditions and regulatory approvals.
strategic Rationale
This acquisition is a meaningful move for Abbott, bolstering its position in the diagnostics market. Exact Sciences is best known for its Cologuard at-home colorectal cancer screening test. Combining Exact Sciences’ innovative cancer screening technologies with Abbott’s broad diagnostic capabilities and global reach is expected to accelerate the adoption of early cancer detection.
Exact Sciences is projected to generate more than $3 billion in revenue this year, demonstrating strong organic sales growth. upon completion of the transaction, Abbott’s diagnostic sales are anticipated to exceed $12 billion annually. This will position Abbott as a leader in the rapidly growing field of molecular diagnostics.
Future Operations and Leadership
Following the closing of the acquisition, Exact Sciences will operate as a subsidiary of Abbott. The company will maintain its presence in Madison, Wisconsin. Kevin Conroy, the current CEO of Exact Sciences, will transition to an advisory role to support the integration with Abbott and further advance the company’s mission to end cancer.Exact Sciences’ press release details this transition.
Key Takeaways
- Acquisition Value: $18.8 billion (cash and stock)
- Closing Date: Expected in the second quarter of 2026
- Strategic Focus: Strengthens Abbott’s diagnostic portfolio,particularly in cancer screening.
- Revenue Impact: Abbott’s diagnostic sales projected to exceed $12 billion annually.
- Location: Exact Sciences will maintain a presence in Madison, Wisconsin.
FAQ
What is Cologuard? Cologuard is a non-invasive, at-home colorectal cancer screening test developed by Exact Sciences. Learn more about Cologuard here.
What does this mean for Exact Sciences shareholders? Exact Sciences shareholders will receive $77.50 in cash plus 0.15 shares of abbott stock for each share of Exact Sciences they own.
What is Abbott’s overall strategy in diagnostics? Abbott is focused on expanding its leadership in diagnostics through innovation and strategic acquisitions, aiming to provide a broad range of diagnostic solutions to healthcare providers and patients worldwide.